Pfizer has launched Zavicefta (ceftazidime-avibactam) for adults hospitalised with serious infections caused by aerobic Gram-negative bacteria. Zavicefta combines the beta-lactam antibiotic ceftazidime with the beta-lactamase inhibitor, avibactam.

Pfizer says that ceftazidime-avibactam is effective against some “resistant aerobic Gram-negative pathogens of greatest global concern”, such as carbapenem-resistant Enterobacteriaceae and multi-drug resistant Pseudomonas aeruginosa.

Recommended

Verapamil for rhinosinusitis?

Verapamil dramatically improves symptom scores in patients with chronic rhinosinusitis and nasal polyps

NSAIDs and paracetamol linked to hearing loss

NSAIDs and paracetamol might increase the risk of hearing loss, according to an analysis of 55,850 women

Popular

Achieving Excellence welcomed by profession

Pharmacy bodies give thumbs up to Scotland’s latest strategy for the profession with its focus firmly on pharmaceutica...

EHC row: value and price are not the same thing

By Pharmacy Magazine editor, Richard Thomas. The row over the cost of EHC from pharmacies – and the overwrought tone o...

Mike Smith celebrates 50 years in pharmacy

Pharmacy grandee Mike Smith is celebrating 50 years in the profession this year. “I can’t believe it”, he says